Syndax Pharmaceuticals (NASDAQ: SNDX) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.
This table compares Syndax Pharmaceuticals and Onconova Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Syndax Pharmaceuticals and Onconova Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Syndax Pharmaceuticals presently has a consensus target price of $26.43, indicating a potential upside of 194.30%. Onconova Therapeutics has a consensus target price of $7.33, indicating a potential upside of 618.95%. Given Onconova Therapeutics’ higher probable upside, analysts plainly believe Onconova Therapeutics is more favorable than Syndax Pharmaceuticals.
Institutional and Insider Ownership
59.9% of Syndax Pharmaceuticals shares are held by institutional investors. Comparatively, 25.5% of Onconova Therapeutics shares are held by institutional investors. 24.1% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 27.3% of Onconova Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Syndax Pharmaceuticals has a beta of 3.97, meaning that its share price is 297% more volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500.
Earnings & Valuation
This table compares Syndax Pharmaceuticals and Onconova Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Syndax Pharmaceuticals||$1.22 million||179.53||-$44.47 million||($2.68)||-3.35|
|Onconova Therapeutics||$5.55 million||1.98||-$19.66 million||($2.77)||-0.37|
Onconova Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals beats Onconova Therapeutics on 8 of the 13 factors compared between the two stocks.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.